Nurix, Gilead extend research term for oncology program by two years for $10 million fee

Bitget2026/10/05 11:03

Nurix Therapeutics extended the research term for an undisclosed oncology program under its strategic collaboration with Gilead by two years. Extension marks the second two-year renewal for the program under the 2019 agreement. Nurix will receive a USD 10 million research term extension fee under the amended deal. Nurix can opt into co-development with 50/50 US profit-sharing on up to two programs, subject to restrictions. Deal economics include potential payments of up to about USD 1.3 billion, tied to fees and milestone events. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nurix Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610050700PRIMZONEFULLFEED9838803) on October 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

Michael Saylor releases bitcoin Tracker information again, possibly hinting at increasing BTC holdings

BlockBeats•2026/10/11 12:13

Crypto Pundit Says If You Are Holding XLM, Read This

TimesTabloid•2026/10/11 12:00

International gold prices are approaching the $4,200 mark, and Wall Street is bullish on next week's market.

新浪财经•2026/10/11 11:05

Only 1.45 Billion Shiba Inu (SHIB) Burned in 24 Hours Hints at Reversal

UToday•2026/10/11 10:27